Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B

Summary

Cardiac bypass surgery is an important treatment for patients with severely blocked arteries (tubes that delivery oxygen and nutrients to the heart). Hundreds of thousands of these operations are done each year to help relieve patients' chest pain and to prevent future heart attacks. The surgery is done by "bypassing" blood flow around badly clogged arteries by sewing on healthy vessels from another part of the body (usually from the leg or the chest). Aspirin (a blood thinner) is given to patients once a day after their surgery because it stops "sticky" cells in the blood (platelets) from blocking these new vessels (which may lead to a future heart attack).

Research has shown that aspirin does not work as well in people after they have bypass surgery as the investigators might expect (for reasons that are not fully understood). One reason aspirin may not work as well after surgery is because the body makes many more platelets after surgery than it would under normal circumstances. All of these new platelets overwhelm the aspirin and continue to be "sticky" and ready to block off arteries. The investigators believe that giving multiple daily doses of aspirin following bypass surgery is more effective at blocking platelet activity than giving aspirin once daily.

Conditions

• Postoperative Dysfunction Following Cardiac Surgery

Interventions

DRUG

Aspirin

Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.

DRUG

Aspirin

Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.

DRUG

Aspirin

Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.

Sponsors & Collaborators

• Hamilton Health Sciences Corporation

  lead OTHER

Principal Investigators

• Jeremy Paikin, MD · Cardiology Fellow

• John Eikelboom, MBBS · Hematologist, PHRI researcher

• Richard Whitlock, MD · Cardiac Surgeon, PHRI researcher

• Guillaume Pare, MD · Medical Biochemist, PHRI researcher

• Jack Hirsh, MD · Hematologist, Professor Emeritus, PHRI researcher

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-07-31

Primary Completion

2014-03-31

Completion

2014-07-31

Countries

• Canada

Study Locations